for Pain Management
Chronic Pain syndromes have strong impact on the patients’ physical and mental conditions and take a toll on their functional capabilities. Cannabis has been shown to be effective in pain management and patients report a significant improvement in their general wellbeing.
Smoking and inhalation are currently the most commonly used methods for administering medical cannabis. However, the precise concentration of active cannabinoids in inflorescences is inconsistent and difficult to determine. In addition, smoking may have deleterious side effects and social acceptance issues, which may reduce compliance of drug administration.
OWC is developing a cannabinoid-enriched sublingual disintegrating tablet to provide patients who suffer from chronic pain syndromes with a validated and consistent form of drug administration. Such an administration modality will allow for dose adjustment and offer a healthier alternative to smoking. The tablet will be available in various ratios and strengths of CBD/THC in order to achieve optimal efficacy and tolerability.
The following milestones have been completed:
• Development of a second generation tablet formulation has been completed and patent protection has been applied for.
• A Phase I safety and a PK study will be conducted at a leading medical center in Tel Aviv in the first quarter of 2019 as smoking/inhalation substitute
• OWC has obtained a permit from the Israel Medical Cannabis Authority (IMCA) to conduct an efficacy study on chronic pain patients and is filing for an IRB approval in order to initiate the study.